Speaker Name: Prof. Piotr Ponikowski, Institute for Heart Disease, University Hospital, Medical University, Wroclaw, Poland.

Access this expert session to:

• Get familiar with SGLT2 inhibitor benefits in lowering HF events and slowing CKD progression in T2DM or CKD, based on the EMPA-REG OUTCOME, DAPA-CKD, and EMPA-KIDNEY trials.
• Review evidence from the DAPA-HF and EMPEROR-Reduced trials supporting SGLT2 inhibitors as foundational therapy for HFrEF, regardless of diabetes status.
• Explore findings from the EMPEROR-Preserved and DELIVER trials showing reduced HF events in HFpEF across the EF spectrum.
• Gain insight into early in-hospital empagliflozin initiation after acute HF stabilization from the EMPULSE trial.
• Evaluate post-MI HF prevention data from the EMPACT-MI and DAPA-MI trials in high-risk patients.